Harrow (NASDAQ:HROW) Earns Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Harrow (NASDAQ:HROW - Free Report) in a research report sent to investors on Monday,Benzinga reports. HC Wainwright currently has a $57.00 price target on the stock.

Separately, B. Riley reduced their target price on shares of Harrow from $73.00 to $69.00 and set a "buy" rating for the company in a research note on Wednesday, December 4th.

Harrow Stock Down 4.0 %

HROW traded down $0.97 during trading on Monday, hitting $23.09. 229,019 shares of the company's stock were exchanged, compared to its average volume of 502,187. Harrow has a fifty-two week low of $9.86 and a fifty-two week high of $59.23. The stock has a market cap of $823.32 million, a P/E ratio of -24.72 and a beta of 0.46. The business's 50 day moving average is $28.17 and its two-hundred day moving average is $37.54. The company has a quick ratio of 1.44, a current ratio of 1.55 and a debt-to-equity ratio of 3.23.

Harrow (NASDAQ:HROW - Get Free Report) last announced its quarterly earnings results on Thursday, March 27th. The company reported $0.25 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.14. Harrow had a negative net margin of 19.75% and a negative return on equity of 45.57%. The business had revenue of $66.83 million for the quarter, compared to analysts' expectations of $66.01 million. As a group, equities analysts expect that Harrow will post -0.53 earnings per share for the current fiscal year.

Remove Ads

Institutional Investors Weigh In On Harrow

Several large investors have recently made changes to their positions in the business. Vanguard Group Inc. grew its position in Harrow by 0.3% during the fourth quarter. Vanguard Group Inc. now owns 1,872,100 shares of the company's stock valued at $62,809,000 after buying an additional 5,225 shares during the period. Braidwell LP grew its position in shares of Harrow by 106.3% during the 4th quarter. Braidwell LP now owns 907,039 shares of the company's stock valued at $30,431,000 after acquiring an additional 467,401 shares during the period. State Street Corp increased its stake in shares of Harrow by 2.2% during the 3rd quarter. State Street Corp now owns 730,973 shares of the company's stock worth $32,865,000 after purchasing an additional 15,554 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Harrow by 0.6% in the 3rd quarter. Geode Capital Management LLC now owns 722,730 shares of the company's stock worth $32,500,000 after purchasing an additional 3,960 shares during the period. Finally, D. E. Shaw & Co. Inc. lifted its stake in Harrow by 6.7% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 664,714 shares of the company's stock valued at $22,301,000 after purchasing an additional 41,896 shares during the last quarter. 72.76% of the stock is owned by hedge funds and other institutional investors.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.